DC44726 |
Enasidenib Mesylate
|
Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). |
DC28576 |
DS-1001b
|
DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity. |
DC72374 |
(S,S)-GSK321
|
(S,S)-GSK321 is a (S,S)-enantiomer of GSK321. |
DC70642 |
NCATS-SM5637
|
NCATS-SM5637 (NSC 791985) is a potent, selective mutant IDH1 inhibitor with IC50 of 81/72 nM for IDH1 mutant R132H/R132C, respctively.NCATS-SM5637 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations in engineered mIDH1-U87-xenograft mouse model, compared with the approved drug AG-120 (ivosidenib). |
DC49742 |
AGI-12026
|
AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma. |
DC48219 |
Safusidenib
|
Safusidenib is a novel IDH1 inhibitor for the treatment of IDH1-mutated tumors. |